{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Elevated+Risk+for+Melanoma&page=2",
    "query": {
      "condition": "Elevated Risk for Melanoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 27,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Elevated+Risk+for+Melanoma&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Elevated+Risk+for+Melanoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T10:47:49.139Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00912418",
      "title": "Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "autologous tumor cells plus GM-CSF-in Adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Craig L Slingluff, Jr",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 14,
      "start_date": "2000-05-01",
      "completion_date": "2002-10-09",
      "has_results": false,
      "last_update_posted_date": "2020-03-02",
      "last_synced_at": "2026-10-11T10:47:49.139Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00912418"
    },
    {
      "nct_id": "NCT00462280",
      "title": "Lovastatin in Treating Patients At High Risk of Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Precancerous Condition",
        "Stage 0 Melanoma",
        "Stage I Melanoma",
        "Stage II Melanoma"
      ],
      "interventions": [
        {
          "name": "lovastatin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2007-05",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2014-10-31",
      "last_synced_at": "2026-10-11T10:47:49.139Z",
      "location_count": 3,
      "location_summary": "Orange, California • Tampa, Florida • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00462280"
    },
    {
      "nct_id": "NCT03327064",
      "title": "A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-melanoma Skin Cancer"
      ],
      "interventions": [
        {
          "name": "UAB30",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-10-01",
      "completion_date": "2023-08-31",
      "has_results": false,
      "last_update_posted_date": "2024-08-07",
      "last_synced_at": "2026-10-11T10:47:49.139Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03327064"
    },
    {
      "nct_id": "NCT06365619",
      "title": "Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2026-10",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-11T10:47:49.139Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06365619"
    },
    {
      "nct_id": "NCT00492505",
      "title": "Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        },
        {
          "name": "tamoxifen citrate",
          "type": "DRUG"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "San Diego Pacific Oncology & Hematology Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2007-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-01-10",
      "last_synced_at": "2026-10-11T10:47:49.139Z",
      "location_count": 1,
      "location_summary": "Encinitas, California",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00492505"
    },
    {
      "nct_id": "NCT03554083",
      "title": "Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Tiragolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2018-10-05",
      "completion_date": "2025-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-10-11T10:47:49.139Z",
      "location_count": 3,
      "location_summary": "Jacksonville, Florida • Minneapolis, Minnesota • Rochester, Minnesota",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03554083"
    },
    {
      "nct_id": "NCT03693378",
      "title": "A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma",
        "Familial Pancreatic Cancer",
        "FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Immunovia, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1349,
      "start_date": "2016-01-19",
      "completion_date": "2021-11-12",
      "has_results": false,
      "last_update_posted_date": "2022-03-31",
      "last_synced_at": "2026-10-11T10:47:49.139Z",
      "location_count": 13,
      "location_summary": "Stanford, California • New Haven, Connecticut • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03693378"
    },
    {
      "nct_id": "NCT00118313",
      "title": "Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "incomplete Freund's adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "multi-epitope melanoma peptide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tetanus toxoid helper peptide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "dimethyl sulfoxide",
          "type": "DRUG"
        },
        {
          "name": "imiquimod",
          "type": "DRUG"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Craig L Slingluff, Jr",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "12 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "2004-11-04",
      "completion_date": "2006-07-28",
      "has_results": false,
      "last_update_posted_date": "2020-03-27",
      "last_synced_at": "2026-10-11T10:47:49.139Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00118313"
    },
    {
      "nct_id": "NCT02334735",
      "title": "A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "DC Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Montanide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Poly-ICLC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Nina Bhardwaj",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2015-07-01",
      "completion_date": "2020-07-15",
      "has_results": false,
      "last_update_posted_date": "2022-09-15",
      "last_synced_at": "2026-10-11T10:47:49.139Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02334735"
    },
    {
      "nct_id": "NCT05463796",
      "title": "InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer Risk",
        "Cancer Predisposition Syndrome",
        "Hereditary Cancer Prediction",
        "Childhood Cancer Survivors",
        "Adult Cancer Survivors",
        "IARC Carcinogens",
        "Smoking History",
        "Lung Cancer",
        "Ductal/Lobular Carcinoma",
        "Barrett Esophagus",
        "Pancreatic Precursor Lesions",
        "Colonic Dysplasia/Adenomata",
        "Non-Alcoholic Fatty Liver Disease",
        "Non Alcoholic Steatohepatitis",
        "Cirrhosis",
        "High Grade Prostatic Epithelial Neoplasia",
        "High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ",
        "Adenomatous Hyperplasia",
        "High-risk Oral Precancerous Diseases",
        "Melanocytic Lesion, Adult",
        "Hematologic Malignancy",
        "Lung; Node",
        "Serous Tubal Intraepithelial Carcinoma",
        "Endometrial Intraepithelial Neoplasia",
        "Cervical and Endocervical Carcinoma in Situ",
        "Vulvar Intraepithelial Neoplasia",
        "Nephrogenic Rests",
        "Benign Bone Lesions With Risk of Malignant Degeneration",
        "Giant Cell Tumor",
        "Osteochondroma",
        "Spitz Nevus"
      ],
      "interventions": [
        {
          "name": "Samples",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 5000,
      "start_date": "2023-04-25",
      "completion_date": "2031-03-25",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-10-11T10:47:49.139Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05463796"
    }
  ]
}